Grifols Wins Early FDA OK For SCIg Xembify, Setting Stage For Margin Growth

Analysts said Grifols is poised for profit margin growth after the US FDA approved its first 20% subcutaneous immunoglobulin, Xembify, for treating primary immunodeficiencies.